-
1دورية أكاديمية
المؤلفون: Mosenzon, O., Blicher, T.M., Rosenlund, S., Eriksson, J.W., Heller, S., Hels, O.H., Pratley, R., Sathyapalan, T., Desouza, C., Abramof, R., Alpenidze, D., Aronoff, S., Astamirova, K., Barker, B., Bedel, G., Belousova, L., Benson, M., Beshay, I., Biggs, W., Blaze, K., Bogdanski, P., Busch, R., Chaidarun, S., Chandran, S., Chang, A., Chilka, S., Cleland, A., Connery, L., Cornett, G., Delgado, B., Donner, T., Eliasson, K., Eriksson, J., Folkerth, S., Forshaw, K., Frandsen, H.A., Frolova, E., Gandy, W., Gatipon, G., Golovach, A., Gonzalez-Orozco, L., Gumprecht, J., Haddad, E., Hansen, T.K., Hart, T., Hasan, S., Hella, B., Hellgren, M., Hewitt, M., Hietaniemi, S., Hitz, M., Houser, P., Huntley, R., Jackson, R., Jakobsen, P.E., Kapoor, A., Kargina, L., Kazakova, E., Khan, K., Klein, E., Knoble, H., Krasnopeeva (Kabachkova), N., Krzeminski, A., Kunitsyna, M., Lawhead, J., Levin, K., Levin, P., Lewy-Alterbaum, L., Lindmark, S., Lindsay, R., Luts, A., Lysenko, T., Madsbad, S., Maxwell, T., Mbogua, C., Mcknight, J., Metsärinne, K., Milovanova, T., Morawski, E., Nabriski, D., Nguyen, H., Nicol, P., Nieminen, S., Nikkola, A., Norwood, P., O'Donnell, P., Odugbesan, A., Parker, J., Pergaeva, Y., Peskov, A., Plevin, S., Pouzar, J., Reed, J., Rossing, P., Sergeeva-Kondrachenko, M., Shaikh, Z., Shamkhalova, M., Shehadeh, N., Shlesinger, Y., Silver, R., Snyder, B., Soufer, J., Strand, J., Sulosaari, S., Tirosh, A., Traylor, H., Uhlenius, N., Vagapova, G., Yanovskaya, M., Zarutskaya, L., Zhdanova, E.
وصف الملف: text
العلاقة: https://eprints.whiterose.ac.uk/208314/3/PIONEER%205%20primary%20manuscript_for%202nd%20resubmission_18.04.19.docx.pdfTest; Mosenzon, O., Blicher, T.M., Rosenlund, S. et al. (113 more authors) (2019) Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. The Lancet Diabetes & Endocrinology, 7 (7). pp. 515-527. ISSN 2213-8587
-
2دورية أكاديمية
المؤلفون: Mosenzon, Ofri, Blicher, Thalia Marie, Rosenlund, Signe, Eriksson, Jan W, Heller, Simon, Hels, Ole Holm, Pratley, Richard, Sathyapalan, Thozhukat, Desouza, Cyrus, Abramof, R, Alpenidze, D, Aronoff, S, Astamirova, K, Barker, B, Bedel, G, Belousova, L, Benson, M, Beshay, I, Biggs, W, Blaze, K, Bogdanski, P, Busch, R, Chaidarun, S, Chandran, S, Chang, A, Chilka, S, Cleland, A, Connery, L, Cornett, G, Delgado, B, Desouza, C, Donner, T, Eliasson, K, Eriksson, J, Folkerth, S, Forshaw, K, Frandsen, H A, Frolova, E, Gandy, W, Gatipon, G, Golovach, A, Gonzalez-Orozco, L, Gumprecht, J, Haddad, E, Hansen, T K, Hart, T, Hasan, S, Hella, B, Heller, S, Hellgren, M
المساهمون: AstraZeneca, Boehringer Ingelheim, National Institutes of Health, Bristol-Myers Squibb, Novo Nordisk
المصدر: The Lancet Diabetes & Endocrinology ; volume 7, issue 7, page 515-527 ; ISSN 2213-8587
مصطلحات موضوعية: Endocrinology, Endocrinology, Diabetes and Metabolism, Internal Medicine
الإتاحة: https://doi.org/10.1016/s2213-8587Test(19)30192-5
https://api.elsevier.com/content/article/PII:S2213858719301925?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2213858719301925?httpAccept=text/plainTest